Strong in vivo data on Ablynx' antiviral Nanobody

Belgian drug discovery firm Ablynx says it has completed studies showing that antiviral antibodies derived from its Nanobodies platform give  extended protection against viral infection in vivo when administered  via an intrapulmonary route.

In a second study, Ablynx demonstrated in vivo proof-of-concept for a  proprietary novel half-life extension technology which allows the  half-life of its Nanobody-based therapeutics to be tailored depending on  the indication.

Ablynx has demonstrated that antiviral Nanobodies protect against signs  of viral infection and the presence of active virus when delivered via  an intrapulmonary route. Following a single administration of the  Nanobodies via the lungs, neutralization of virus was observed for at  least 72 hours.